Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019; 21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Should old folks who have lived their lives be allowed to place a huge economic burden on the young by using a disproportionate amount of limited Medicare resources for medical care?
A look at current literature and work by a statewide initiative can motivate development of policies that help respond to unrepresented patients’ needs.
AMA J Ethics. 2019; 21(7):E611-616. doi:
10.1001/amajethics.2019.611.